Results 11 to 20 of about 26,051 (185)

Cardiac amyloidosis

Swiss Medical Weekly
Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and ...
Natallia Laptseva, Dominik C. Benz, Rahel Schwotzer, Andreas J. Flammer   +3 more
doaj   +8 more sources

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Diagnostics, 2021
Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li, Damianos Kokkinidis, Xiaobo Xu   +2 more
exaly   +3 more sources

Unraveling cardiac amyloidosis in Egypt: diagnostic challenges and disease outcomes [PDF]

The Egyptian Heart Journal
Background Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of insoluble amyloid fibrils. Despite the growing global recognition of cardiac amyloidosis and the recent development of targeted therapeutic strategies ...
Rasha Mohamed Abayazeed, Ingy Etman, Mahmoud Hassanein, Hagar Mahmoud Kamal, Mohamed Elsakhawy, Ahmed Abdelaaty, Maram Allam, Nouran Soror, Ashraf Elghandour, Mohamed H. Elbahoty, Sara Salama, Osama Mohammed Refai, Noha Elkholy   +12 more
doaj   +2 more sources

Survival Outcomes in Transthyretin Cardiac Amyloidosis in the Tafamidis Era: Real-World Evidence from Greece [PDF]

Diagnostics
Background: Diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM) have increased in recent years, with a growing proportion of patients being identified at earlier disease stages.
Freideriki Eleni Kourti, Alexios S. Antonopoulos, Vasileios Kytinos, Theodoros Tsampras, Alexandrina Kouroutzoglou, Dimitrios Kyriakopoulos, Maria Eleni Koilakou, Pinelopi Karampina, Vasiliki Gardikioti, Dimitrios Terentes-Printzios, Alexandros Kasiakogias, Ioannis Leontsinis, Christina Chrysohoou, Maria Koutelou, Konstantinos Toutouzas, Konstantinos Tsioufis, Charalambos Vlachopoulos   +16 more
doaj   +2 more sources

Light Chain Cardiac Amyloidosis With Skeletal Muscle Weakness [PDF]

JACC: Case Reports
Background: Amyloid light chain (AL) amyloidosis can manifest with heterogeneous, multisystem features. Cardiac involvement is common and drives prognosis.
Elyn Montgomery, BN, PhD, Natasha Gorrie, MD, Georgia McCaughan, BMedSc, MBBS, MMed, James Nadel, BA (Adv), MBBS (Hon I), MMed, PhD, Karan Shahi, MSc, N.K. Bart, MD, PhD, Antonia S. Carroll, BSc (Adv), MBBS   +6 more
doaj   +2 more sources

Smartwatch-Detected Sinus Tachycardia Unmasking AL Cardiac Amyloidosis in a Young Adult [PDF]

JACC: Case Reports
Background: The clinical presentation of immunoglobulin light-chain (AL) can be very heterogenous resulting in delayed diagnosis and treatment. The use of wearable health technology is rapidly expanding.
Grace O'Dea, MB, BCh, BAO, MSc, Peter O'Gorman, MB, BCh, BAO, PhD, Gerard T. Giblin, MB, BCh, BAO, MD   +2 more
doaj   +2 more sources

Cardiac Amyloidosis

Heart Failure Clinics, 2022
Amyloid deposits are defined by their tinctorial properties. Under the light microscope amyloid deposits are eosinophilic and amorphous when stained with hematoxylin and eosin. With Congo red staining the deposits are positive and under polarized light will exhibit green birefringence.
T, Tadokoro, H, Yamamoto, Y, Hyakuna, M, Mohri   +3 more
openaire   +4 more sources

Cardiac amyloidosis [PDF]

Clinical Medicine, 2018
Systemic amyloidosis comprises an uncommon group of disorders caused by the extracellular deposition of misfolded proteins in various organs. Cardiac amyloid deposition, causing an infiltrative/restrictive cardiomyopathy, is a frequent feature of amyloidosis and a major determinant of survival.
Martinez-Naharro, A, Hawkins, PN, Fontana, M   +2 more
openaire   +6 more sources

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

Transplantation Direct, 2022
Background. Heart transplantation in cardiac amyloidosis (CA) patients is possible and generally considered for transplantation if other organs are not affected.
Soulef Guendouz, MD, Philippe Grimbert, MD, PhD, Costin Radu, MD, PhD, Daniel Cherqui, MD, PhD, Chady Salloum, MD, Nicolas Mongardon, MD, PhD, Sami Maghrebi, MD, Karim Belhadj, MD, Fabien Le Bras, MD, Emmanuel Teiger, MD, PhD, Jean-Paul Couetil, MD, PhD, Adriana Balan, MD, Mounira Kharoubi, MSc, Mélanie Bézard, MSc, Silvia Oghina, MD, Diane Bodez, MD, PhD, Luc Hittinger, MD, PhD, Vincent Audard, MD, PhD, Violaine Planté-Bordeneuve, MD, PhD, Alexandre De la Taille, MD, PhD, Eric Bergoend, MD, Valerie Frenkel, MD, PhD, Pascale Fanen, MD, PhD, Vincent Leroy, MD, PhD, Christophe Duvoux, MD, PhD, Maryvonnick Carmagnat, PharmD, Thierry Folliguet, MD, PhD, Thibaud Damy, MD, PhD   +27 more
doaj   +1 more source

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis

eJHaem, 2022
The causal protein of amyloid light‐chain (AL) amyloidosis is a monoclonal immunoglobulin free light chain (mFLC), which must be quantified in the serum for patient diagnosis and monitoring.
Hajer Abroud, Asma Beldi‐Ferchiou, Vincent Audard, François Lemonnier, Fabien Le Bras, Karim Belhadj, Anissa Moktefi, Elsa Poullot, Khalil El Karoui, Jehan Dupuis, Alizée Maarek, Louise Roulin, Marie‐Hélène Delfau‐Larue, Silvia Oghina, Mounira Kharoubi, Mélanie Bézard, Amira Zaroui, Thibaud Damy, Valérie Molinier‐Frenkel   +18 more
doaj   +1 more source